PROSTAMOL-UNO®

Dosage and Administration

Prostamol® Uno is convenient for administration: just one capsule per day. One pack of 30 capsules is enough for a one-month treatment.

The minimum recommended course of admission should be at least three months. Given the fact that prostatic hyperplasia is a progressive disease, the treatment, most likely, will require a long or even constant duration. 

 Side Effects & Contraindications:

The drug is said to be of high safety and good tolerance.

 Note:

The treatment of chronic prostatitis requires a complex approach targeting all the reasons behind the decease. For an additional positive effect of the treatment, patients are advised to adjust their nutrition and lead a more active lifestyle. Experts advise reinforcing the treatment with the consumption of large volumes of fresh water. Prevention of the inflammatory process also includes perineal massage and physiotherapeutic procedures.

Analogs:

Prostaplant, Longidaza, Vitaprost, Prostagut, Permixon, Penopen, Permikson, Prostess, ProstOptima, ProstaSabal, etc.

Prostatitis is an inflammation of the prostate. There are two types of prostatitis in men: acute and chronic. Acute prostatitis develops because of a bacterial infection in the prostate gland. Manifestations of chronic prostatitis include: urgent urination, perineal pain, sexual dysfunction, etc. According to modern scientific data, long-term chronic prostatitis can be one of the causes of the onset and progression of prostatic hyperplasia.

Prostate adenoma is a benign prostatic hyperplasia. With age, the risk of the development of the prostate adenoma increases significantly. Statistics says that about half of men over 50 y.o. complain about symptoms in the lower urinary tract caused by prostatic hyperplasia. The reasons for the occurrence of adenoma have not been fully identified, but the most probable reason behind it is a certain hormonal rearrangement of the body, which causes the growth of the so-called adenomatous tissue in the prostate. In this case, as a rule, a compression of the urethra occurs, normal outflow of urine is disrupted, and men begin to experience various kinds of unpleasant sensations.

The role of phyto preparations in the treatment of symptoms of the lower urinary tract associated with benign prostatic hyperplasia (BPH) remains the subject of much research and debate. Preparations of Serenoa repens are of a peculiar interest among the plant extracts. In Russia and the CIS countries, a drug that is quite frequently prescribed and highly evaluated by physicians is Prostamol® Uno.

Its main component is the Serenoa repens (saw palmetto) fruit extract, which is endemic to the southeastern coast of the United States. The first use of the extract for the treatment of urinary tract disorders is attributed to American Indians. The extract demonstrates antiproliferative, antiandrogenic, anti-inflammatory and anti-edematous effects, selectively manifested at the level of the prostate gland. The drug does not affect the levels of sex hormones in the blood plasma; it does not affect the potency and libido, and does not change the level of specific prostatic antigen in the blood plasma.

Being an herbal urological agent Prostamol® Uno is effective in reducing the following symptoms:

  • Rapid urination, especially at night;
  • Weak or interrupted stream of urine;
  • Dribbling of urine;
  • Feeling of incomplete emptying of the bladder;
  • Pain during urination;
  • Sexual dysfunction.

  1. Gerber GS et al (2001). Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. https://www.ncbi.nlm.nih.gov/pubmed/11744467
  2. Mazo EB, Dmitriev DG (2001). Clinical effect of the drug "Prostamol-Uno" in patients with benign prostatic hyperplasia and chronic prostatitis. https://www.ncbi.nlm.nih.gov/pubmed/11641979
  3. Seregin SP et al (2002). Effect of prostamol-Uno on oxidative and local immune status in patients with benign prostatic hyperplasia and chronic prostatitis. https://www.ncbi.nlm.nih.gov/pubmed/12357892
  4. Vinarov AZ et al (2006). Efficiency and safety of prostamol-Uno in patients with chronic abacterial prostatitis. https://www.ncbi.nlm.nih.gov/pubmed/16550824
  5. Razumov SV, Egorov AA (2007). Expediency of switching from combined therapy with prostamol Uno and alpha-1-adrenoblockers to monotherapy with prostamol Uno in patients with prostatic adenoma. https://www.ncbi.nlm.nih.gov/pubmed/17724829
  6. Trapeznikova MF et al (2008). Prostamol-Uno treatment in patients with prostatic adenoma and chronic non-infectious prostatitis. https://www.ncbi.nlm.nih.gov/pubmed/19069494
  7. Agbabiaka TB et al (2009). Serenoa repens (saw palmetto): a systematic review of adverse events. https://www.ncbi.nlm.nih.gov/pubmed/19591529
  8. Parsons JK (2010). Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors. https://www.ncbi.nlm.nih.gov/pubmed/21475707
  9. Sinescu I et al (2011). Long-term efficacy of Serenoa repens treatment in patients with mild and moderate symptomatic benign prostatic hyperplasia. https://www.ncbi.nlm.nih.gov/pubmed/21304222
  10. Scaglione F et al (2012). Comparison of the potency of 10 different brands of Serenoa repens extracts. https://www.ncbi.nlm.nih.gov/pubmed/22774395
  11. Aliaev IuG et al (2013). The results of the 10-year study of efficacy and safety of Serenoa repens extract in patients at risk of progression of benign prostatic hyperplasia. https://www.ncbi.nlm.nih.gov/pubmed/24159762
  12. Ooi SL, Pak SC (2017). Serenoa repens for Lower Urinary Tract Symptoms / Benign Prostatic Hyperplasia: Current Evidence and Its Clinical Implications in Naturopathic Medicine. https://www.ncbi.nlm.nih.gov/pubmed/28436684
  13. Paterniti I et al (2018). Effects of different natural extracts in an experimental model of benign prostatic hyperplasia (BPH). https://www.ncbi.nlm.nih.gov/pubmed/29679313
  14. Cannarella R et al (2019). Non-hormonal treatment for male infertility: the potential role of Serenoa repens, selenium and lycopene. https://www.ncbi.nlm.nih.gov/pubmed/31002161
  15. Magri V et al (2019). Multidisciplinary approach to prostatitis. https://www.ncbi.nlm.nih.gov/pubmed/30655633
  16. De Nunzio C et al (2020). Inflammation is a target of medical treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia. https://www.ncbi.nlm.nih.gov/pubmed/32060633
  17. Russo GI et al (2020). Clinical Efficacy of Serenoa repens Versus Placebo Versus Alpha-blockers for the Treatment of Lower Urinary Tract Symptoms / Benign Prostatic Enlargement: A Systematic Review and Network Meta-analysis of Randomized Placebo-controlled Clinical Trials. https://www.ncbi.nlm.nih.gov/pubmed/31952967


Type: Unknown Type




CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT